Shared Resources-Cancer Genetic Counseling

共享资源-癌症遗传咨询

• 批准号: 7513322
• 负责人: Ellen Tzivia Matloff
• 金额: $ 2.94万
• 依托单位: YALE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-08-09 至 2012-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7513322
• 关键词: APC gene; Accounting; Adenomatous Polyposis Coli; Adult; Area; Basal cell carcinoma; Basic Science; CDKN2A gene; Cancer Center; Carcinogen Metabolism; Carcinogenesis Mechanism; Caring; Cells; Charge; Chemopreventive Agent; Chromatin Structure; Clinical; Clinical Management; Collaborations; Colon Carcinoma; Community Clinical Oncology Program; Complement; DNA; DNA Repair; Development; Diagnosis; Direct Costs; Discipline of obstetrics; Environmental Carcinogens; Epidemiologist; Epidemiology; Event; Frequencies; Funding; Gene Expression; Gene Expression Regulation; Gene Mutation; Genes; Genetic; Genetic Counseling; Genetic Polymorphism; Genetic Predisposition to Disease; Genetic Programming; Genetic Variation; Genomics; Germ-Line Mutation; Goals; Grant; Group Meetings; Growth; Gynecology; Hereditary Disease; Hereditary Malignant Neoplasm; Hereditary Melanoma; Human Genome; Immune; Individual; Inherited; Institution; Investigation; Joints; Laboratories; Laboratory Scientists; Leadership; Link; Maintenance; Malignant Childhood Neoplasm; Malignant Neoplasms; Methods; Mismatch Repair; Molecular Analysis; Molecular Genetics; Molecular Virology; Mutate; Mutation; Neoplasms; Oncology Group; Operative Surgical Procedures; PTCH gene; Paper; Patients; Peer Review; Pharmaceutical Preparations; Phenotype; Population; Predisposition; Prevalence; Prevention; Primary Health Care; Process; Publishing; Regulation; Relative Risks; Research; Research Personnel; Resource Sharing; Retinoblastoma; Risk; Risk Factors; Role; Scientist; Series; Services; Signal Transduction Pathway; Skin; Skin Cancer; Stem cells; Sun Exposure; Support Groups; Susceptibility Gene; Testing; Therapeutic Radiology specialty; Universities; base; cancer genetics; cancer risk; cancer therapy; cancer type; cell growth; cost; design; environmental agent; functional genomics; gene function; genetic variant; genome-wide analysis; improved; insight; interest; medical schools; melanoma; member; method development; molecular oncology; neoplastic; novel; oncology; polyposis; programs; research study; technology development; trait; tumor; tumor progression

The Program in Gene Regulation and Functional Genomics (GRFGP) is derived from the former Molecular Oncology Program (MOP) which was renamed to reflect a more sharpened focus. The reorganization reflects the profound developments that have occurred in the molecular genetics of cancer, as well as in the broader field of genomics, since the last competitive renewal of this grant. Under the joint leadership of Dr. Jeffrey Sklar and Dr. Sherman Weissman (former co-Leader of MOP), the GRFGP is designed to promote (1) research into the mechanisms and effects of gene expression relevant to the neoplastic phenotype, and (2) the investigation of cancer-associated broad-based structural and functional features of the human genome. These two aspects of the GRFGP cover the study of individual genes that contribute to the development and progression of cancer as well as the analysis of genome-wide gene expression, chromatin structure, and regulatory factors that characterize or control the neoplastic state. Furthermore, the goals of the research encompassed by this program include the development of methods to better elucidate and analyze the changes in genes, gene expression, and DNA related to cancer. Finally, this program is interested in both the biologic processes underlying cancer and the application of information about those processes to the improved prevention, diagnosis, and treatment of cancer. By focusing predominantly on the molecular analysis of sporadic cancers, the GRFGP complements the activities of the Cancer Genetics Program, which is charged with the identification and analysis of genes responsible for hereditary predisposition to cancer. The two Programs engage in significant collaborations, particularly in the area of technology development. The goals of the GRFGP are accomplished through joint sponsorship of the Molecular Virology and Oncology group meetings, major participation in the Stem Cell weekly group meetings, organization of the weekly Genetics Seminar series, institution of Pilot Grant program to stimulate programmatically-oriented research in cancer, as well as by facilitating collaboration between members within the program and other Cancer Center programs. The GRFGP consists of 20 independent but interactive members belonging to eight departments of the Medical School or University. Total peer-reviewed funding support of this group is approximately $4.7 million direct costs annually ($7.5 million total costs), of which just under $1 million direct costs ($1.4 total costs) come from NCI. Total direct funding is $4,79 million ($7.65 million total costs). During the previous grant period, members of this program published 208 cancer-related papers, of which 5.3% were intraprogrammatic and 15.9% inter-programmatic.

基因调控和功能基因组学（GRFGP）的程序源自前一个分子 肿瘤学计划（MOP）被更名为反映更加锐化的重点。重组 反映了癌症分子遗传学以及 自从这笔赠款的最后一个竞争性更新以来，基因组学领域的广泛领域。在博士的共同领导下 Jeffrey Sklar和Sherman Weissman博士（MOP的前共同领导），GRFGP旨在促进 （1）研究与肿瘤表型相关的基因表达的机理和作用，以及 （2）研究人类与癌症相关的广泛结构和功能特征的研究 基因组。 GRFGP的这两个方面涵盖了对各个基因的研究，这有助于 癌症的发展和进展以及全基因组基因表达，染色质的分析 特征或控制肿瘤状态的结构和调节因素。此外，目标的目标 该计划所包含的研究包括开发方法以更好地阐明和 分析与癌症有关的基因，基因表达和DNA的变化。最后，这个程序是 对癌症的生物过程以及有关这些过程的应用感兴趣 改善癌症预防，诊断和治疗的过程。通过主要关注 零星癌的分子分析，GRFGP补充了癌症遗传学的活性 计划，负责识别和分析负责遗传的基因 癌症的易感性。这两个计划进行了重要的合作，特别是在 技术发展。 GRFGP的目标是通过共同赞助的 分子病毒学和肿瘤学组会议，主要参与干细胞每周组 会议，每周遗传研讨会系列的组织，试点赠款计划刺激计划 通过癌症以及通过促进成员之间的合作的程序性研究 在计划和其他癌症中心计划中。 GRFGP由20个属于八个部门的独立但互动成员组成 医学院或大学。该小组的同行评审的总筹款支持约为470万美元 每年直接成本（750万美元的总费用），其中直接成本不到100万美元（1.4美元的总费用） 来自NCI。直接资金的总资金为479万美元（总成本为765万美元）。在上一个赠款期间 该计划的成员发表了208篇与癌症相关的论文，其中5.3％是磁内图 和15.9％的程序间。